The Tumor Immunoenvironment

Front Matter....Pages i-xvi
Role of the Immunological Environment in Cancer Initiation, Development and Progression....Pages 1-12
Front Matter....Pages 13-13
The Metastatic Microenvironment....Pages 15-38
Tumor Infiltration by Immune Cells: Pathologic Evaluation and a Clinical Significance....Pages 39-82
Immunologic Interpretation of Cancer Biology: Impact on Clinical Outcome....Pages 83-104
Front Matter....Pages 105-105
Development of Antitumor Cellular Immunity....Pages 107-133
The Versatile World of Inflammatory Chemokines in Cancer....Pages 135-175
Inflammation, Tumor Progression, and Immune Suppression....Pages 177-196
Pleiotropic and Differential Functions of IL-1α and IL-1β Shape the Tumor Microenvironment and Affect the Outcome of Malignancies....Pages 197-222
Impact of Obesity and Aging on the Tumor Immuno-Environment....Pages 223-250
Front Matter....Pages 251-251
MHC Class I Antigens and the Tumor Microenvironment....Pages 253-286
Tumor-Produced Immune Regulating Factors....Pages 287-306
Roles of Signaling Pathways in Cancer Cells and Immune Cells in Generation of Immunosuppressive Tumor-Associated Microenvironments....Pages 307-323
T Cell Mulfunction in the Tumor Environment....Pages 325-338
Signaling of Tumor-Induced Immunosuppression of Dendritic Cells....Pages 339-360
Tumor Microenvironment may Shape the Function and Phenotype of NK Cells Through the Induction of Split Anergy and Generation of Regulatory NK Cells....Pages 361-381
Front Matter....Pages 383-383
The Role of Myeloid Derived Suppressor Cells in Cancer....Pages 385-404
Macrophage Differentiation and Activation States in the Tumor Microenvironment....Pages 405-430
Dendritic Cells and Cancer: Development, Dysfunction and Therapeutic Targets....Pages 431-455
The Role of Tumor Associated Neutrophils in Cancer....Pages 457-478
Mast Cell Modulation of the Tumor Microenvironment....Pages 479-509
Front Matter....Pages 383-383
Regulatory T Cells in Patients with Cancer....Pages 511-523
Tumor-Evoked Regulatory B Cells as Important Mediators of Cancer Escape....Pages 525-546
Front Matter....Pages 547-547
Cancer Immunotherapy: Overview in Brief....Pages 549-565
Programming of MDSC: New Opportunities for Targeted Therapy....Pages 567-584
Therapeutic Targeting Regulatory T Cells in Tumor....Pages 585-602
ChemoImmunoModulation: Focus on Myeloid Regulatory Cells....Pages 603-619
Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing....Pages 621-642
Prophylactic Cancer Vaccines....Pages 643-660
Front Matter....Pages 661-661
Approaches to Immunologic Monitoring of Clinical Trials....Pages 663-694
Evaluation of the Tumor Immunoenvironment in Clinical Trials....Pages 695-706
Analysis of Myeloid-Derived Suppressor Cells in Patients with Cancer....Pages 707-723
When Results of T cell Immune Monitoring Match/Do Not Match Clinical Outcomes of Tumor Vaccine Trials: What More Could and Should We Measure?....Pages 725-740
Back Matter....Pages 741-745